These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 11008205

  • 21. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R, Schaaf A, Dorn-Beineke A, Allgayer H, Sütterlin M, Marx A, Stroebel P.
    Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
    [Abstract] [Full Text] [Related]

  • 22. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [Abstract] [Full Text] [Related]

  • 23. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F, Jia S, Xing G, Gao L, Zhang L, He F.
    DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
    [Abstract] [Full Text] [Related]

  • 24. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S, Vrhovec I, Svetic B, Cufer T.
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [Abstract] [Full Text] [Related]

  • 25. Plasminogen Activation System in Rectal Adenocarcinoma.
    Razik E, Kobierzycki C, Grzegrzolka J, Podhorska-Okolow M, Drag-Zalesinska M, Zabel M, Dziegiel P.
    Anticancer Res; 2015 Nov; 35(11):6009-15. PubMed ID: 26504024
    [Abstract] [Full Text] [Related]

  • 26. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
    Cantero D, Friess H, Deflorin J, Zimmermann A, Bründler MA, Riesle E, Korc M, Büchler MW.
    Br J Cancer; 1997 Nov; 75(3):388-95. PubMed ID: 9020484
    [Abstract] [Full Text] [Related]

  • 27. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer.
    Seetoo DQ, Crowe PJ, Russell PJ, Yang JL.
    J Surg Oncol; 2003 Mar; 82(3):184-93. PubMed ID: 12619063
    [Abstract] [Full Text] [Related]

  • 28. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
    Borgfeldt C, Bendahl PO, Gustavsson B, Långström E, Fernö M, Willén R, Grenman S, Casslén B.
    Int J Cancer; 2003 Nov 20; 107(4):658-65. PubMed ID: 14520707
    [Abstract] [Full Text] [Related]

  • 29. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
    Nakanishi K, Kawai T, Torikata C, Aurues T, Ikeda T.
    Cancer; 1998 Feb 15; 82(4):724-32. PubMed ID: 9477106
    [Abstract] [Full Text] [Related]

  • 30. High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.
    Thummarati P, Wijitburaphat S, Prasopthum A, Menakongka A, Sripa B, Tohtong R, Suthiphongchai T.
    World J Gastroenterol; 2012 Jan 21; 18(3):244-50. PubMed ID: 22294827
    [Abstract] [Full Text] [Related]

  • 31. Serine proteinase activation in esophageal cancer.
    Tang WH, Friess H, Kekis PB, Martignoni ME, Fukuda A, Roggo A, Zimmerman A, Büchler MW.
    Anticancer Res; 2001 Jan 21; 21(4A):2249-58. PubMed ID: 11724279
    [Abstract] [Full Text] [Related]

  • 32. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
    Bauer TW, Fan F, Liu W, Johnson M, Parikh NU, Parry GC, Callahan J, Mazar AP, Gallick GE, Ellis LM.
    Ann Surg; 2005 May 21; 241(5):748-56; discussion 756-8. PubMed ID: 15849510
    [Abstract] [Full Text] [Related]

  • 33. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C, Yu J, Huang S.
    Mol Carcinog; 2007 Mar 21; 46(3):165-75. PubMed ID: 17186542
    [Abstract] [Full Text] [Related]

  • 34. Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells.
    He C, He P, Liu LP, Zhu YS.
    J Cancer Res Clin Oncol; 2001 Mar 21; 127(3):180-6. PubMed ID: 11260863
    [Abstract] [Full Text] [Related]

  • 35. Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients.
    Halamkova J, Kiss I, Pavlovsky Z, Tomasek J, Jarkovsky J, Cech Z, Tucek S, Hanakova L, Moulis M, Zavrelova J, Man M, Benda P, Robek O, Kala Z, Penka M.
    Neoplasma; 2011 Mar 21; 58(5):377-85. PubMed ID: 21744990
    [Abstract] [Full Text] [Related]

  • 36. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor.
    Mohanam S, Chintala SK, Go Y, Bhattacharya A, Venkaiah B, Boyd D, Gokaslan ZL, Sawaya R, Rao JS.
    Oncogene; 1997 Mar 20; 14(11):1351-9. PubMed ID: 9178895
    [Abstract] [Full Text] [Related]

  • 37. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
    Pedersen H, Brünner N, Francis D, Osterlind K, Rønne E, Hansen HH, Danø K, Grøndahl-Hansen J.
    Cancer Res; 1994 Sep 01; 54(17):4671-5. PubMed ID: 8062262
    [Abstract] [Full Text] [Related]

  • 38. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
    Pavón MA, Arroyo-Solera I, Céspedes MV, Casanova I, León X, Mangues R.
    Oncotarget; 2016 Aug 30; 7(35):57351-57366. PubMed ID: 27385000
    [Abstract] [Full Text] [Related]

  • 39. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
    Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, Schildberg FW.
    J Clin Oncol; 1995 Aug 30; 13(8):2084-93. PubMed ID: 7636552
    [Abstract] [Full Text] [Related]

  • 40. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
    Baker EA, Bergin FG, Leaper DJ.
    Mol Pathol; 2000 Dec 30; 53(6):307-12. PubMed ID: 11193049
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.